Skip to main content

Main menu

  • Home
  • Issues
    • Issue in progress
    • Issues by date
  • Sections
    • Editorial
    • Review
    • Research
    • Commentary
    • Psychopharmacology for the Clinician
    • Letters to the Editor
  • Topic Collections
  • Instructions for Authors
    • Overview for authors
    • Submission checklist
    • Editorial policies
    • Publication fees
    • Submit a manuscript
    • Dr. Francis Wayne Quan Memorial Prize
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • CJS
    • JAMC

User menu

Search

  • Advanced search
JPN
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • CJS
    • JAMC
JPN

Advanced Search

  • Home
  • Issues
    • Issue in progress
    • Issues by date
  • Sections
    • Editorial
    • Review
    • Research
    • Commentary
    • Psychopharmacology for the Clinician
    • Letters to the Editor
  • Topic Collections
  • Instructions for Authors
    • Overview for authors
    • Submission checklist
    • Editorial policies
    • Publication fees
    • Submit a manuscript
    • Dr. Francis Wayne Quan Memorial Prize
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • Subscribe to our alerts
  • RSS feeds
  • Follow JPN on Twitter
Psychopharmacology for the Clinician

Generic formulations of psychotropic medications and treatment response

Venkat Bhat and Howard C. Margolese
J Psychiatry Neurosci March 01, 2017 42 (2) E3-E4; DOI: https://doi.org/10.1503/jpn.160004
Venkat Bhat
From the Department of Psychiatry, McGill University, Montreal, Que., Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Howard C. Margolese
From the Department of Psychiatry, McGill University, Montreal, Que., Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

A 44-year-old man experienced his first major depressive episode 2 years ago and responded well to 150 mg/d of sertraline. He was on no other medications. He relapsed (sadness, psycho-motor retardation, decreased energy, concentration, sleep and appetite) after continuing the same dose of sertraline for 1 year. He did not report any precipitating factors that could have contributed to the relapse, but when asked about the possibility of a switch of his generic medications just before the relapse, he remembered that the pharmacist dispensed a different generic sertraline as it was the only one available in the pharmacy at that moment. Because the patient had been symptom-free for a year with the previous generic sertraline before relapse, the pharmacist was then asked to dispense the previous generic version. The patient noticed substantial improvement and achieved remission from his depressive symptoms within 2 months. Since then, he has continued to take the same generic sertraline at 150 mg/d and has been in remission.

Generic versions of brand-name psychotropic medications, particularly generic antidepressants, can constitute more than 70% of all psychiatric prescriptions.1 Cost considerations have driven the increased use of generics, but long-term cost-benefit efficacy has not been unequivocally demonstrated.2–6 No rigorously designed large-scale studies comparing generic and brand-name psychotropics have been reported, and many case reports of altered therapeutic response (TR) and side effects (SE) associated with generic switches have been published.3,7 A minority of generic switches appear to be associated with adverse TR and SE, but it is difficult to identify this minority a priori.

Generics, in contrast to brand-name medications, are not required to undergo efficacy and safety studies before being marketed.8 Bioequivalence studies of generics involve single-dose studies in young, healthy volunteers, and are then generalized to patient populations that can vary by numerous parameters, such as age, sex, race and disorder.9–11 A recently published study in a clinical setting examined switching from brand-name to generic olanzapine in patients with schizophrenia and found lower serum olanzapine concentrations associated with the switch.12 Although no short-term symptomatic changes were noted, the study raised concerns about long-term symptom control and suggested that generic substitution be considered a potential indication for therapeutic drug monitoring.12,13

For pharmacokinetic bioequivalence, the generic and brand-name medication must have maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve (AUC) falling within the range of 0.80 to 1.25 to be within the 90% confidence interval.14 Thus, variance among generics could be especially large if they are at opposite ends of these confidence intervals. While bioequivalence is demonstrated for the active ingredient, the actual pharmacokinetic parameters could differ owing to varying excipients in different generics. Among psychotropic medications, most published adverse TRs and SEs with switches from brand-name to generic medications have been with anticonvulsants and mood stabilizers owing to the narrower therapeutic index of these medications.3 Several case reports and systematic reviews on emergence of adverse TRs and SEs have been published on antidepressant, antipsychotic and anxiolytic brand-name to generic switches.3,6,15,16

The case vignette was an interesting instance of relapse involving a switch from one generic medication to another. There were no SEs associated with the generic switch, and the prior TR was reproduced when the patient reverted to the previous generic medication. The potential for drug variability may be greater when switching between generics than when switching from a brand-name to a generic medication.12 This variability is of salience with increasing availability and use of generics in an aging population. In a minority of patients, bioequivalence does not equate to pharmacodynamic and clinical equivalence, and this should be considered in the context of rapid emergence of altered TR and SE among stable patients. When confirmed, a “no substitution” order for brand or generic medications can be specified. Clinicians and patients are often unaware of generic switches by the pharmacy, and it is important to explore this possibility in the context of altered TRs or SEs in patients who were previously stable on their medications.3,17

Footnotes

  • Competing interests: H.C. Margolese reports grants from Amgen, BMS, Envivo, Lundbeck, Janssen and Roche; and personal fees from BMS, Janssen, Lundbeck, Novartis, Otsuka, Sunovian, Perdue and Shire outside the submitted work

  • The information in this column is not intended as a definitive treatment strategy but as a suggested approach for clinicians treating patients with similar histories. Individual cases may vary and should be evaluated carefully before treatment is provided. The patient described in this column is a composite with characteristics of several real patients.

References

  1. ↵
    1. Mark TL,
    2. Kassed C,
    3. Levit K,
    4. et al
    .An analysis of the slowdown in growth of spending for psychiatric drugs, 1986–2008.Psychiatr Serv 2012;63:13–8.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Carbon M,
    2. Correll CU
    .Rational use of generic psychotropic drugs.CNS Drugs 2013;27:353–65.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Desmarais JE,
    2. Beauclair L,
    3. Margolese HC
    .Switching from brand-name to generic psychotropic medications: a literature review.CNS Neurosci Ther 2011;17:750–60.
    OpenUrlCrossRefPubMed
    1. Gothe H,
    2. Schall I,
    3. Saverno K,
    4. et al
    .The impact of generic substitution on health and economic outcomes: a systematic review.Appl Health Econ Health Policy 2015;13Suppl 1S21–33.
    OpenUrl
    1. Colombo GL,
    2. Agabiti-Rosei E,
    3. Margonato A,
    4. et al
    .Off-patent generic medicines vs. off-patent brand medicines for six reference drugs: a retrospective claims data study from five local healthcare units in the Lombardy Region of Italy.PLoS One 2013;8:e82990
    OpenUrlCrossRefPubMed
  4. ↵
    1. Wu EQ,
    2. Yu AP,
    3. Lauzon V,
    4. et al
    .Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.Ann Pharmacother 2011;45:441–51.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Margolese HC,
    2. Wolf Y,
    3. Desmarais JE,
    4. et al
    .Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching.Int Clin Psychopharmacol 2010;25:180–2.
    OpenUrlPubMed
  6. ↵
    1. Kumet R,
    2. Gelenberg AJ
    .The effectiveness of generic agents in psychopharmacologic treatment.Essent Psychopharmacol 2005;6:104–11.
    OpenUrlPubMed
  7. ↵
    1. Unterecker S,
    2. Proft F,
    3. Riederer P,
    4. et al
    .The comparison of brand-name and generic formulations of venlafaxine: a therapeutic drug monitoring analysis.Ther Drug Monit 2014;36:269–72.
    OpenUrl
    1. Tothfalusi L,
    2. Endrenyi L
    .Approvable generic carbamazepine formulations may not be bioequivalent in target patient populations.Int J Clin Pharmacol Ther 2013;51:525–8.
    OpenUrl
  8. ↵
    1. Samuel R,
    2. Attard A,
    3. Kyriakopoulos M
    .Mental state deterioration after switching from brand-name to generic olanzapine in an adolescent with bipolar affective disorder, autism and intellectual disability: a case study.BMC Psychiatry 2013;13:244
    OpenUrl
  9. ↵
    1. Italiano D,
    2. Bruno A,
    3. Santoro V,
    4. et al
    .Generic olanzapine substitution in patients with schizophrenia: assessment of serum concentrations and therapeutic response after switching.Ther Drug Monit 2015;37:827–30.
    OpenUrl
  10. ↵
    1. Hiemke C,
    2. Baumann P,
    3. Bergemann N,
    4. et al
    .AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.Pharmacopsychiatry 2011;44:195–235.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Blier P
    .Generic medications: another variable in the treatment of illnesses.J Psychopharmacol 2007;21:459–60.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Spina E,
    2. Santoro V,
    3. D’Arrigo C
    .Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.Clin Ther 2008;30:1206–27.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Bobo WV,
    2. Stovall JA,
    3. Knostman M,
    4. et al
    .Converting from brand-name to generic clozapine: a review of effectiveness and tolerability data.Am J Health Syst Pharm 2010;67:27–37.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Blier P
    .Brand versus generic medications: the money, the patient and the research.J Psychiatry Neurosci 2003;28:167–8.
    OpenUrl
PreviousNext
Back to top

In this issue

Journal of Psychiatry and Neuroscience: 42 (2)
J Psychiatry Neurosci
Vol. 42, Issue 2
1 Mar 2017
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on JPN.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Generic formulations of psychotropic medications and treatment response
(Your Name) has sent you a message from JPN
(Your Name) thought you would like to see the JPN web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Generic formulations of psychotropic medications and treatment response
Venkat Bhat, Howard C. Margolese
J Psychiatry Neurosci Mar 2017, 42 (2) E3-E4; DOI: 10.1503/jpn.160004

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Generic formulations of psychotropic medications and treatment response
Venkat Bhat, Howard C. Margolese
J Psychiatry Neurosci Mar 2017, 42 (2) E3-E4; DOI: 10.1503/jpn.160004
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Alerts
  • RSS

Authors & Reviewers

  • Overview for Authors
  • Submit a manuscript
  • Manuscript Submission Checklist

About

  • General Information
  • Staff
  • Editorial Board
  • Contact Us
  • Advertising
  • Reprints
  • Copyright and Permissions
  • Accessibility
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1180-4882.

All editorial matter in JPN represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.
To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected].
View CMA's Accessibility policy.

Powered by HighWire